FDASRA Act of 2022

Hozzl · 2022-12-29T18:33:45Z

Explore the details of Senate Bill 4535 FDASRA Act of 2022 currently in Congress. Get insights into its purpose, current status, sponsors, and potential impact on Health. Stay informed on legislative developments.

12/29/2022, 6:33 PM

Congressional Summary of S 4535

Food and Drug Administration Simple Reauthorization Act of 2022 or the FDASRA Act of 2022

This bill reauthorizes the authority of the Food and Drug Administration to collect certain fees related to drugs, medical devices, and biosimilar biological products and modifies such fees, including the base fee amounts.

Read the Full Bill

Formatted Text PDF Formatted XML

Current Status of Bill S 4535

Bill S 4535 is currently in the status of Bill Introduced since July 14, 2022. Bill S 4535 was introduced during Congress 117 and was introduced to the Senate on July 14, 2022. Bill S 4535's most recent activity was Read twice and referred to the Committee on Health, Education, Labor, and Pensions. as of July 14, 2022

Bipartisan Support of Bill S 4535

Total Number of Sponsors

Democrat Sponsors

Republican Sponsors

Unaffiliated Sponsors

Total Number of Cosponsors

Democrat Cosponsors

Republican Cosponsors

Unaffiliated Cosponsors

Policy Area and Potential Impact of Bill S 4535

Primary Policy Focus

Health

Alternate Title(s) of Bill S 4535

FDASRA Act of 2022

Food and Drug Administration Simple Reauthorization Act of 2022

Biosimilar User Fee Amendments of 2022

Generic Drug User Fee Amendments of 2022

Medical Device User Fee Amendments of 2022

Prescription Drug User Fee Amendments of 2022

A bill to amend the Federal Food, Drug, and Cosmetic Act to revise and extend the user-fee programs for prescription drugs, medical devices, generic drugs, and biosimilar biological products, and for other purposes.